Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety

Ferla, Salvatore ORCID: https://orcid.org/0000-0002-5918-9237, Bassetto, Marcella ORCID: https://orcid.org/0000-0002-2491-5868, Pertusati, Fabrizio ORCID: https://orcid.org/0000-0003-4532-9101, Kandil, Sahar ORCID: https://orcid.org/0000-0003-1806-9623, Westwell, Andrew D. ORCID: https://orcid.org/0000-0002-5166-9236, Brancale, Andrea ORCID: https://orcid.org/0000-0002-9728-3419 and McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X 2016. Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety. Bioorganic and Medicinal Chemistry Letters 26 (15) , pp. 3636-3640. 10.1016/j.bmcl.2016.06.001

Preview

PDF - Accepted Post-Print Version Download (676kB) | Preview

Abstract

Prostate cancer is a major cause of male death worldwide and the identification of new and improved treatments is constantly required. Among the available options, different non-steroidal androgen receptor (AR) antagonists are approved also to treat castration-resistant forms. Most of these drugs show limited application due to the development of resistant mutants of their biological target. Following docking-based studies on a homology model for the AR open antagonist conformation, a series of novel 3,5-bis-trifluoromethylphenyl compounds was designed with the aim to improve the antiproliferative activity of anti-androgen drugs bicalutamide and enzalutamide. The new structural modifications might impede the receptor to adopt its closed agonist conformation also in the presence of adaptive mutations. Among the novel compounds synthesised, several displayed significantly improved in vitro activity in comparison with the parent structures, with IC50 values in the low micromolar range against four different prostate cancer cell lines (LNCaP, VCaP, DU-145, 22Rv1). Selected hits demonstrated full AR antagonistic behaviour and promising candidates for further development were identified.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	Homology modelling; Rational drug design; Prostate cancer; Androgen-receptor
Additional Information:	This work is dedicated to the memory of Prof. Chris McGuigan, a great colleague and scientist, invaluable source of inspiration and love for research.
Publisher:	Elsevier
ISSN:	0960-894X
Date of First Compliant Deposit:	6 June 2016
Date of Acceptance:	1 June 2016
Last Modified:	07 Nov 2024 01:30
URI:	https://orca.cardiff.ac.uk/id/eprint/91515

Citation Data

Cited 14 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item